menu

CME: Insights from the Latest Clinical Trials in Lung Cancer

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Insights from the Latest Clinical Trials in Lung Cancer

close
0.25 credits
15 minutes
Insights from the Latest Clinical Trials in Lung Cancer
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Related
Comments
  • Overview

    In spite of the available evidence supporting the critical need for molecular testing to help determine which treatment is best for patients with non-small cell lung cancer, better strategies are needed to change how and when molecular testing occurs in the diagnostic journey. To help overcome this challenge as well as the challenges related to the initiation and sequencing of treatment with immunotherapies and TKIs in patients with lung cancer, Drs. Mark A. Socinski and Tarek M. Mekhail sit down together to dive into the latest insights from the 2019 ESMO Asia Congress.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Tarek M. Mekhail, MD, MSC, FRCSI, FRCSEd
    Consulting Fees: AstraZeneca, BMS, Merck, Roche, Takeda

    Mark A. Socinski, MD
    Commercial Interest Speakers Bureau: AstraZeneca, BMS, Bayer, Genentech, Guardant Health, Novartis
    Contracted Research: AstraZeneca, Genentech, Molecular Partners, Spectrum

    Reviewers/Content Planners/Authors:

    • Ann Early has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Nick Lombardi has ownership interest with Vertex Pharmaceuticals.
    • Brian P. McDonough, MD, FAAFP has nothing to disclose.
    • William Mencia, MD, FACEHP, CHCP has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify appropriate first-line molecular testing in NSCLC that can be used to impact treatment selection.
    • Evaluate evidence from clinical trials on the effectiveness and safety of approved and emerging ALK-, EGFR-, and ROS1-therapies regarding current treatment paradigms.
  • Target Audience

    This activity is designed to meet the educational needs of oncologists and oncology nurses.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Merck and Takeda Oncology.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    In spite of the available evidence supporting the critical need for molecular testing to help determine which treatment is best for patients with non-small cell lung cancer, better strategies are needed to change how and when molecular testing occurs in the diagnostic journey. To help overcome this challenge as well as the challenges related to the initiation and sequencing of treatment with immunotherapies and TKIs in patients with lung cancer, Drs. Mark A. Socinski and Tarek M. Mekhail sit down together to dive into the latest insights from the 2019 ESMO Asia Congress.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Tarek M. Mekhail, MD, MSC, FRCSI, FRCSEd
    Consulting Fees: AstraZeneca, BMS, Merck, Roche, Takeda

    Mark A. Socinski, MD
    Commercial Interest Speakers Bureau: AstraZeneca, BMS, Bayer, Genentech, Guardant Health, Novartis
    Contracted Research: AstraZeneca, Genentech, Molecular Partners, Spectrum

    Reviewers/Content Planners/Authors:

    • Ann Early has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Nick Lombardi has ownership interest with Vertex Pharmaceuticals.
    • Brian P. McDonough, MD, FAAFP has nothing to disclose.
    • William Mencia, MD, FACEHP, CHCP has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify appropriate first-line molecular testing in NSCLC that can be used to impact treatment selection.
    • Evaluate evidence from clinical trials on the effectiveness and safety of approved and emerging ALK-, EGFR-, and ROS1-therapies regarding current treatment paradigms.
  • Target Audience

    This activity is designed to meet the educational needs of oncologists and oncology nurses.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Merck and Takeda Oncology.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 9/20/20